U.S. Regenerative Medicine Market Size & Outlook
U.S. regenerative medicine market, 2018-2030 (US$M)
Related Markets
U.S. regenerative medicine market highlights
- The U.S. regenerative medicine market generated a revenue of USD 16,810.8 million in 2023 and is expected to reach USD 49,319.4 million by 2030.
- The U.S. market is expected to grow at a CAGR of 16.6% from 2024 to 2030.
- In terms of segment, therapeutics was the largest revenue generating product in 2023.
- Banks is the most lucrative product segment registering the fastest growth during the forecast period.
Regenerative medicine market data book summary
| Market revenue in 2023 | USD 16,810.8 million |
| Market revenue in 2030 | USD 49,319.4 million |
| Growth rate | 16.6% (CAGR from 2023 to 2030) |
| Largest segment | Therapeutics |
| Fastest growing segment | Banks |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Therapeutics, Tools, Banks, Services |
| Key market players worldwide | AstraZeneca PLC, Roche Holding AG, Integra Lifesciences Holdings Corp, Astellas Pharma Inc, Cook Group, Bayer AG, Pfizer Inc, Merck KGaA, Abbott Laboratories, Vericel Corp, Novartis AG ADR, GlaxoSmithKline |
Other key industry trends
- In terms of revenue, U.S. accounted for 55.2% of the global regenerative medicine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. regenerative medicine market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 49,319.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Regenerative Medicine Market Scope
Regenerative Medicine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. regenerative medicine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to regenerative medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 75.87% in 2023. Horizon Databook has segmented the U.S. regenerative medicine market based on therapeutics, tools, banks, services covering the revenue growth of each sub-segment from 2018 to 2030.
The UK is anticipated to witness significant growth over the forecast period due to increased investments by various big companies and governments, including the NHS & research laboratories. For instance, in March 2022, the government of the UK invested USD 347 million to accelerate healthcare research and manufacturing. An additional fund of USD 80 million would help companies at the forefront of the invention with their commercial-scale manufacturing investments in areas like gene & cell therapies and improved diagnostic technologies.
Such increasing investments in gene and cell therapies are anticipated to propel the regenerative medicine market. Moreover, increasing clinical trials and the rising approvals for gene & cell therapies in the country are expected to support the market competition. For instance, in March 2023, Great Britain approved CSL’s Hemgenix as the first gene therapy for adults suffering from hemophilia B.
Reasons to subscribe to U.S. regenerative medicine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. regenerative medicine market databook
-
Our clientele includes a mix of regenerative medicine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. regenerative medicine market , including forecasts for subscribers. This country databook contains high-level insights into U.S. regenerative medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. regenerative medicine market size, by product, 2018-2030 (US$M)
U.S. Regenerative Medicine Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
